AU2011205485B2 - Compounds and methods - Google Patents
Compounds and methods Download PDFInfo
- Publication number
- AU2011205485B2 AU2011205485B2 AU2011205485A AU2011205485A AU2011205485B2 AU 2011205485 B2 AU2011205485 B2 AU 2011205485B2 AU 2011205485 A AU2011205485 A AU 2011205485A AU 2011205485 A AU2011205485 A AU 2011205485A AU 2011205485 B2 AU2011205485 B2 AU 2011205485B2
- Authority
- AU
- Australia
- Prior art keywords
- amino
- methyl
- pyrimidinyl
- benzenesulfonamide
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29463710P | 2010-01-13 | 2010-01-13 | |
| US61/294,637 | 2010-01-13 | ||
| PCT/US2011/020798 WO2011088027A1 (en) | 2010-01-13 | 2011-01-11 | Compounds and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011205485A1 AU2011205485A1 (en) | 2012-08-02 |
| AU2011205485B2 true AU2011205485B2 (en) | 2014-09-25 |
Family
ID=44304601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011205485A Expired - Fee Related AU2011205485B2 (en) | 2010-01-13 | 2011-01-11 | Compounds and methods |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120329784A1 (enExample) |
| EP (1) | EP2523559A4 (enExample) |
| JP (1) | JP2013517273A (enExample) |
| KR (1) | KR20120114355A (enExample) |
| CN (1) | CN102791131A (enExample) |
| AU (1) | AU2011205485B2 (enExample) |
| BR (1) | BR112012017277A2 (enExample) |
| CA (1) | CA2786999A1 (enExample) |
| EA (1) | EA201290642A1 (enExample) |
| IL (1) | IL220812A0 (enExample) |
| MX (1) | MX2012008141A (enExample) |
| SG (1) | SG182351A1 (enExample) |
| WO (1) | WO2011088027A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013164323A1 (en) * | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| KR102230461B1 (ko) * | 2013-03-15 | 2021-03-22 | 유니버시티 오브 써던 캘리포니아 | 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들 |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| CN104844526B (zh) * | 2015-04-16 | 2018-08-31 | 温州医科大学 | 一种4,6-嘧啶二胺类化合物及其制备方法和应用 |
| CN106008366A (zh) * | 2016-05-25 | 2016-10-12 | 山东大学 | 一种利匹韦林的制备方法 |
| JP6165373B1 (ja) * | 2017-02-24 | 2017-07-19 | タマ化学工業株式会社 | ピリジン−３−スルホニルクロリドの製造方法 |
| ES2975690T3 (es) | 2017-05-26 | 2024-07-11 | Cancer Research Tech Ltd | Inhibidores de BCL6 derivados de benzimidazolona |
| ES2939776T3 (es) | 2018-04-13 | 2023-04-26 | Cancer Research Tech Ltd | Inhibidores de BCL6 |
| CN108864052A (zh) * | 2018-06-07 | 2018-11-23 | 福建医科大学 | 一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用 |
| EP4206196A1 (en) * | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| US20250177391A1 (en) * | 2022-02-23 | 2025-06-05 | President And Fellows Of Harvard College | Inhibitors of ddr1 and ddr2 for the treatment of arthritis |
| TW202345809A (zh) | 2022-03-23 | 2023-12-01 | 美商愛德亞生物科學公司 | 作為parg抑制劑之經哌取代的吲唑化合物 |
| US11891362B1 (en) * | 2023-04-14 | 2024-02-06 | King Faisal University | N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents |
| WO2024243304A2 (en) * | 2023-05-23 | 2024-11-28 | Quantx Biosciences Us, Inc. | Bicyclic heteroaryl compounds |
| WO2024249831A2 (en) * | 2023-06-02 | 2024-12-05 | Unogen Biotech Ltd. | Triple kinase inhibitors |
| WO2024250010A2 (en) * | 2023-06-02 | 2024-12-05 | Atomwise Inc. | Inhibitors of tyk2 |
| WO2025096550A1 (en) * | 2023-10-31 | 2025-05-08 | Twine Therapeutics, Inc. | Methods of treating cardiomyopathy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080242681A1 (en) * | 2004-01-22 | 2008-10-02 | Altana Pharma Ag | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW504510B (en) * | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
| WO2003002544A1 (en) * | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
| WO2004087707A1 (en) * | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| CN1910159A (zh) * | 2004-01-16 | 2007-02-07 | 诺瓦提斯公司 | 2,4－二氨基嘧啶和它们用于诱导心肌发生的用途 |
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CA2628283C (en) * | 2005-11-01 | 2017-06-27 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| UA109412C2 (uk) * | 2005-11-01 | 2015-08-25 | 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки | |
| JP2009540013A (ja) * | 2006-06-15 | 2009-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アニリノ−４−（複素環）アミノ−ピリミジン |
| CN101589036A (zh) * | 2006-12-19 | 2009-11-25 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的氨基嘧啶 |
| WO2008118822A1 (en) * | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| AU2008314632B2 (en) * | 2007-10-19 | 2015-05-28 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
-
2011
- 2011-01-11 AU AU2011205485A patent/AU2011205485B2/en not_active Expired - Fee Related
- 2011-01-11 EA EA201290642A patent/EA201290642A1/ru unknown
- 2011-01-11 US US13/520,861 patent/US20120329784A1/en not_active Abandoned
- 2011-01-11 KR KR1020127021083A patent/KR20120114355A/ko not_active Withdrawn
- 2011-01-11 BR BR112012017277A patent/BR112012017277A2/pt not_active IP Right Cessation
- 2011-01-11 CA CA2786999A patent/CA2786999A1/en not_active Abandoned
- 2011-01-11 CN CN2011800138247A patent/CN102791131A/zh active Pending
- 2011-01-11 MX MX2012008141A patent/MX2012008141A/es unknown
- 2011-01-11 EP EP11733258.5A patent/EP2523559A4/en not_active Withdrawn
- 2011-01-11 SG SG2012049409A patent/SG182351A1/en unknown
- 2011-01-11 WO PCT/US2011/020798 patent/WO2011088027A1/en not_active Ceased
- 2011-01-11 JP JP2012549000A patent/JP2013517273A/ja active Pending
-
2012
- 2012-07-05 IL IL220812A patent/IL220812A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080242681A1 (en) * | 2004-01-22 | 2008-10-02 | Altana Pharma Ag | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120114355A (ko) | 2012-10-16 |
| IL220812A0 (en) | 2012-08-30 |
| WO2011088027A8 (en) | 2012-08-30 |
| CA2786999A1 (en) | 2011-07-21 |
| AU2011205485A1 (en) | 2012-08-02 |
| BR112012017277A2 (pt) | 2017-10-03 |
| SG182351A1 (en) | 2012-08-30 |
| US20120329784A1 (en) | 2012-12-27 |
| WO2011088027A1 (en) | 2011-07-21 |
| CN102791131A (zh) | 2012-11-21 |
| EP2523559A1 (en) | 2012-11-21 |
| MX2012008141A (es) | 2012-08-03 |
| JP2013517273A (ja) | 2013-05-16 |
| EP2523559A4 (en) | 2013-11-06 |
| EA201290642A1 (ru) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011205485B2 (en) | Compounds and methods | |
| JP6180426B2 (ja) | パーキンソン病の処置のためのキナーゼｌｒｒｋ２モジュレーターとしての２−（フェニル又はピリド−３−イル）アミノピリミジン誘導体 | |
| KR101258504B1 (ko) | 히스톤 데아세틸라제의 억제제 | |
| CN108290879B (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
| US7928140B2 (en) | Benzothiazole PI3 kinase modulators for cancer treatment | |
| US20100113445A1 (en) | Chemical Compounds | |
| MD3810602T2 (ro) | Compuşi | |
| JP5575799B2 (ja) | ７−フェノキシクロマンカルボン酸誘導体 | |
| CN112638373A (zh) | 细胞周期蛋白依赖性激酶抑制剂 | |
| CA2683624A1 (en) | Pharmaceutical compounds | |
| EP2552211A1 (en) | Indazolyl-pyrimidines as kinase inhibitors | |
| EP1917262A1 (en) | Piperidine and piperazine derivatives as p2x3 antagonists | |
| KR20130138734A (ko) | 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물 | |
| CZ20031748A3 (en) | Pyrimidineamines as angiogenesis modulators | |
| AU2008207809A1 (en) | Anthranilamide inhibitors of aurora kinase | |
| CN103958482A (zh) | 作为lrrk2调节剂的氨基嘧啶衍生物 | |
| WO2006031806A2 (en) | 2-thiopyrimidinones as therapeutic agents | |
| AU2015268961A1 (en) | MTH1 inhibitors for treatment of cancer | |
| AU2010315361B2 (en) | Quinazoline compounds | |
| WO2022199589A1 (zh) | 嘧啶衍生物 | |
| WO2011088031A1 (en) | Compounds and methods | |
| WO2023146512A1 (en) | Compounds and methods of use thereof | |
| JP4834441B2 (ja) | ピリミジニルアルキルチオ基を有する新規環式化合物 | |
| RU2838187C2 (ru) | Соединения | |
| ES2359953T3 (es) | Derivados de pirimidina como inhibidores de la fosfatidilinositol-3-kinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |